Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration (KOALA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04236440
Recruitment Status : Active, not recruiting
First Posted : January 22, 2020
Last Update Posted : February 21, 2021
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:

The researchers in this study want to learn how drug BAY2586116 works in patients with obstructive sleep apnea (OSA). OSA is a sleep disorder marked by breathing pauses during sleep due to repetitive obstructions of the upper airway. BAY2586116 is a new drug under development for the treatment of OSA. It blocks protein channels expressed on the surface of the upper airways in small mechanoreceptors (a type of molecule that sense and pass stimulus outside a cell on to the inside of the cell through mechanical gate on the surface of the cell). Thus the negative pressure reflex alerting the brain of inspiration is triggered more easily leading to a stronger activation of throat muscles. This prevents narrowing or collapse of the upper airways during sleep which is one of the pathological key factors in OSA.

Researchers also want to find out if participants experience any medical problems during the study. And they study the effects of different routes of administration (drops in nose or spray in nose or throat) and different doses of the test drug. Patients participating this study will undergo two study parts: in Part A, participants will receive both the test drug and placebo (a placebo looks like the test drug but does not have any medicine in it); in Part B, participants will receive the test drug twice via different routes of administration (drops in nose or spray in nose or throat). Sleeps of the participants will be monitored by medical equipment. Participants will be asked to visit the clinic 7 times in 12 weeks in total.


Condition or disease Intervention/treatment Phase
Sleep Apnea, Obstructive Drug: BAY2586116 (A1) Drug: Placebo (A2) Drug: BAY2586116 (B1) Drug: BAY2586116 (B2) Drug: BAY2586116 (B3) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Part A: placebo-controlled 2-way crossover Part B: fixed single sequence
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Part A: Randomized, double-blind Part B: Open-label
Primary Purpose: Treatment
Official Title: Proof-of-mechanism Single-center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate Pharmacodynamics, Safety, Tolerability and Exposure of BAY2586116 (Part A) and an Open-label Comparison of Different Application Modes for Single Nasal/Pharyngeal Dose Administrations (Part B) in 12 Participants With Obstructive Sleep Apnea
Actual Study Start Date : February 4, 2020
Estimated Primary Completion Date : April 23, 2021
Estimated Study Completion Date : June 11, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arm Intervention/treatment
Experimental: Part A: A1A2 + Part B

Part A: Participants will receive a single dose administration of BAY2586116 (A1) in treatment period 1, and a single dose administration of placebo (A2) in treatment period 2.

Part B: After successfully completing Part A, participants will proceed to Part B of the study.

Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.

Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).

Drug: BAY2586116 (A1)
160 μg BAY2586116 (nasal spray administration)

Drug: Placebo (A2)
Placebo matching BAY2586116 (nasal spray administration)

Drug: BAY2586116 (B1)
160 μg BAY2586116 (nasal drops)

Drug: BAY2586116 (B2)
80 μg BAY2586116 (nasal spray)

Drug: BAY2586116 (B3)
160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)

Experimental: Part A: A2A1 + Part B

Part A: Participants will receive a single dose administration of placebo (A2) in treatment period 1, and a single dose administration of BAY2586116 (A1) in treatment period 2.

Part B: After successfully completing Part A, participants will proceed to Part B of the study.

Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.

Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).

Drug: BAY2586116 (A1)
160 μg BAY2586116 (nasal spray administration)

Drug: Placebo (A2)
Placebo matching BAY2586116 (nasal spray administration)

Drug: BAY2586116 (B1)
160 μg BAY2586116 (nasal drops)

Drug: BAY2586116 (B2)
80 μg BAY2586116 (nasal spray)

Drug: BAY2586116 (B3)
160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)




Primary Outcome Measures :
  1. Critical closing pressure (Pcritgs) of the upper airway (cmH2O) during sleep with a polysomnography [ Time Frame: From start of sleep to end of sleep of administration day (Day 1) ]

Secondary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: From first application of study intervention up to 2 days after end of treatment with study intervention in each period ]
  2. Severity of treatment-emergent adverse events (TEAEs) [ Time Frame: From first application of study intervention up to 2 days after end of treatment with study intervention in each period ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant must be 18 years of age or above at the time of signing the informed consent.
  • Participants need to be diagnosed with OSA but should be considered otherwise healthy at the discretion of the investigator.
  • Participants do not need to be on CPAP therapy at the time of the study. However, if they are on therapy, participants must commit to keep their treatment schedule constant during the study period, especially the night before each administration of study intervention. For participants on CPAP, this will be monitored objectively using the compliance chip within the CPAP devices.
  • Female of non-child bearing potential or male.
  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Female participants:

      -- i. Participants of non-childbearing potential, i.e. post-menopausal (no menses for at least 1 year) or surgically sterile (documented history of tubal ligation, hysterectomy or bilateral oophorectomy).

    2. Male participants:

      • i. Male participants of reproductive potential must agree to utilize two reliable and acceptable methods of contraception simultaneously when sexually active. This applies for the time period between admission to the study site until 12 weeks after the last administration of the study intervention.

Acceptable methods of contraception include, but are not limited to, (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based contraception.

  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Ability to understand and follow study-related instructions.
  • The informed consent must be signed before any study specific tests or procedures are done.

Exclusion Criteria:

  • Severely impaired breathing within two days prior to randomization (e.g. acute nasal congestion during upper airway infection).
  • Subject with known allergies or hypersensitivities to the study drugs (active substances or excipients of the preparations).
  • Any other condition which at the discretion of the investigator would make the participant unsuitable for participation in the study and will not allow participation for the full planned study period (e.g. active malignancy or other condition limiting life expectancy to less than 12 months).
  • Use of any topical medication containing local anesthetics for nose and throat within 2 days before each administration of study intervention.
  • Donation of more than 100 mL of plasma or equivalent volume of blood within 4 weeks or 500 mL whole blood within 3 months before study drug administration.
  • Previous participation in this study.
  • Participation in another clinical study with study intervention(s) within 90 days prior to first administration.
  • Heavy smoking, i.e. more than 20 cigarettes per day.
  • Light smokers who are unable to cease smoking for the duration of the inhouse phases of the study (i.e. Study day 1 in treatment periods 1, 2, 3 and 4).
  • Drug or alcohol abuse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04236440


Locations
Layout table for location information
Australia, South Australia
Adelaide Institute for Sleep Health
Bedford Park, South Australia, Australia, 5042
Sponsors and Collaborators
Bayer
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT04236440    
Other Study ID Numbers: 20732
First Posted: January 22, 2020    Key Record Dates
Last Update Posted: February 21, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases